IBRX Stock Analysis
IB
Uncovered
Immunitybio Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 725 full-time employees. The company went IPO on 2015-07-28. The firm is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its segment is focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Its platforms include antibody cytokine fusion proteins; DNA, RNA, and recombinant protein vaccine technologies, including self-amplifying RNA, second-generation adenovirus hAd5 vector and recombinant protein platforms; toll-like receptor activating adjuvants; natural killer (NK) cell therapy, including off-the-shelf NK cells, and autologous and allogenic memory-like cytokine-enhanced NK cells (M-ceNK); damage-associated molecular patterns inducers, including Aldoxorubicin and Nanatinostat. Its clinical pipeline consists of over 26 clinical trials of which 17 are in Phase I or III development, across 13 indications in liquid and solid tumors.